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Abstract: Objectives: To assess whether mean corpuscular volume (MCV) is useful in detecting non-adherence to AZT-
containing therapy. 
Design: Observational study within randomised controlled trial. 
Methods: We combined data from two treatment arms in SPARTAC, an RCT of short-course cART in primary HIV 
infection, classifying participants as responders (HIV-RNA decrease 1 log10 or reaching <400copies/ml) or non-
responders following cART initiation. We assessed the sensitivity and specificity of using different percentage increases 
in MCV for accurately differentiating between responders and non-responders. We further examined changes in MCV 
levels up to 24 weeks after protocol-indicated cART cessation. 
Results: Of 119 participants included in this analysis, 73 (61%) were women, 71 of whom were randomised in Africa. 
Ninety-eight (88%) and 84 (85%) were classified as responders at 4 and 12 weeks respectively following cART initiation. 
MCV increased by a mean 3% and 1% at week 4, and 14% and <1% at 12 weeks for responders and non-responders. A 
2% MCV increase at 4 weeks had 62% sensitivity and specificity for identifying virological response. At 12 weeks, an 8% 
increase had 89% sensitivity and specificity. In responders, MCV remained lower for individuals in African compared to 
non-African sites throughout and rose from 85 vs 90 fL at cART start to 96 vs 103 fL at 12 weeks post-initiation then fell 
to 88 vs 93 fL and 86 vs 89 fL at 12 and 48 weeks post-cessation. 
Conclusion: In low-income countries, where HIV RNA may be unavailable, 12-weekly MCV measurements may be 
useful in monitoring adherence to AZT-containing regimens. 
Keywords: HIV, MCV, adherence, anti-HIV therapy, low-income countries, HIV RNA. 
INTRODUCTION 
  The main aim of combination anti-retroviral therapy 
(cART) in HIV infection is the suppression of viral 
replication resulting in an improvement in immune function 
and clinical outcomes [1, 2]. Viral suppression, as measured 
by HIV RNA quantification, provides crucial information for 
monitoring the efficacy and success of cART and reflects 
treatment adherence. Maintaining a high level of adherence 
to cART is the most important predictor of therapeutic 
success, in terms of restoration of immune function and 
improvement of overall survival [3]. 
  In high-income country settings, HIV RNA is generally 
performed 3-4 times per year once patients initiate cART. 
Currently at $20-50 per assay, excluding laboratory costs,   
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however, the test is generally not affordable in countries with 
the world’s heaviest HIV burden, sub-Saharan Africa. 
Current standard recommendations for assessing and 
initiating second-line ART in this setting suggest waiting 
until clinically-overt immunological function has 
deteriorated [4], by which time extensive resistance may 
have developed [5], compromising the efficacy of first-line 
therapy. Early detection of reduced adherence to cART, with 
appropriate support, could potentially reverse this scenario, 
and may confer enhanced potency of first-line regimens. 
Given that, in most Sub-Saharan African settings, there are 
only two widely-available ART lines of therapy, 
preservation of function of first- line, usually also more cost-
effective [6], is highly desirable. Alternative methods for 
assessing adherence have been sought which can be used 
before clinical manifestations of profound immune 
compromise are evident. 
  Although a number of methods for assessing adherence 
to medication are available, these mostly rely on self-
reporting and may not be indicative of true levels of 
adherence as they are subject to reporting bias [7-10]. One 46    The Open AIDS Journal, 2012, Volume 6  Mugisha et al. 
biological test which has been proposed is the comparison of 
erythrocyte size, as determined by the mean corpuscular 
volume (MCV), measured pre-treatment and following 
initiation. MCV measurement is standard on modern fully-
automated haematology instruments that use light scatter 
technology. A dilute red cell suspension passes single file in 
front of a light source and scattered light is detected by a 
photomultiplier and is converted to an electrical impulse. 
The degree of scatter is proportional to the surface areas of 
the erythrocyte thus providing an estimation of cell volume. 
MCV is an important initial test in the assessment of 
anaemia and is the standard test for the diagnosis of micro 
and macrocytic anaemia [11], which was observed to occur 
when nucleoside reverse-transcriptase inhibitor drugs 
(NRTIs), particularly zidovudine (AZT) and stavudine (d4T) 
are used to treat HIV infection [12-15]. 
  MCV has been proposed as a surrogate marker of 
adherence to zidovudine. However, its usefulness as an 
adherence measure has never been adequately assessed. 
There has been some focus on the association of MCV levels 
with self-reported adherence [12, 13] and HIV RNA levels 
while on therapy [16] which have shown that MCV levels 
rise linearly for approximately the first 24 weeks of adherent 
treatment before reaching a steady state, and that both MCV 
absolute value, and change from baseline at time points after 
this, are highly associated with HIV RNA levels. However, it 
has not been confirmed whether, and for how long, MCV 
levels remain high following the cessation of therapy. 
  We evaluate MCV levels while on cART and after 
stopping it in participants enrolled onto SPARTAC, a 
randomised controlled trial of short-term therapy in primary 
HIV infection (PHI). HIV RNA and MCV levels were 
measured at all trial visits including randomisation, on 
cART, upon protocol-indicated stopping of cART, and 
thereafter. 
METHODS 
  We used data from SPARTAC (Short Pulse Anti-
Retroviral Therapy At HIV Seroconversion- ISRCTN76 
742797), an international multi-centre randomized controlled 
trial comparing three different strategies of intervention in 
PHI; 12 weeks of cART, 48 weeks of cART, or no ART. 
Enrolment for SPARTAC was completed in July 2007 and 
the trial reported in July 2011 [17]. The study includes 366 
patients from two African countries (Uganda and South 
Africa) and several sites in Europe (UK, Ireland, Spain, and 
Italy), as well as Australia and Brazil. 
  At each visit, HIV RNA was measured and blood 
specimens collected to measure a variety of laboratory 
parameters. Full blood counts (FBC) and MCV were 
performed using one of four analyzers; Beckman Coulter 
AcT 5 Diff (Beckman Coulter Inc, Fullerton, CA), Coulter 
LH 750 (Beckman Coulter Inc) Sysmex XE-2100 (Sysmex, 
UK), or the Advia 2120 haematology system (Siemens 
Healthcare diagnostics Inc) [18]. As samples were stored at 
4-8 ºC and processed within 10 hours, any variation by 
analyzer used is likely to be minimal [19]. 
  Participants were also requested to complete a self-
administered adherence questionnaire at each visit. 
  The trial was approved by ethics committees in each of 
the participating countries and participants signed a written 
informed consent. 
Statistical Methods 
  SPARTAC participants randomised to 12 or 48 weeks of 
AZT-containing cART, in whom pre-treatment MCV was 
measured, were eligible for inclusion in the current analyses. 
Subjects with a baseline HIV RNA <400 copies/ml were 
excluded. We describe MCV at baseline and 4 and 12 weeks 
after initiation of cART. Measurements had to be taken 
within a two-week window of each time point. Participants 
were classified as responders if they achieved an HIV RNA 
<400 copies/ml or a decrease 1 log10 at weeks 4 and12 and 
at cessation of their allocated cART, as a proxy for 
adherence, and non-responders otherwise. Data for the 
analysis of MCV on cART are censored at cART cessation. 
  Using the pre-cART MCV level as baseline, the 
percentage change in MCV after 4 and 12 weeks was 
calculated. The sensitivity and specificity of the change in 
MCV in correctly differentiating responders from non-
responders was assessed using the change in HIV RNA level 
as the gold standard. We also undertook a sensitivity analysis 
using a stricter definition for response (HIV RNA <400 
copies/ml or a decrease 2 log10 copies/ml). 
  We also compared self-reported adherence levels at 
weeks 4 and 12 from the question “During the past 4 days, 
on how many days have you missed taking all (or part) of 
your doses?” against our classification of virological 
response as well as MCV levels. 
  Furthermore, we described changes in MCV levels 4, 12, 
and 24 weeks (within 2 weeks) following the cessation of 
cART and compared these to levels at cART cessation. For 
participants on the 12-week cART arm, this was at the 16, 24 
and 36-week visits, respectively. For those on the 48-week 
arm the corresponding visits were at weeks 52, 60 and 72. 
Follow-up was censored at the re-initiation of cART if 
earlier. Analysis post cART cessation was restricted to 
participants who had achieved virological response. 
RESULTS 
  Of 243 SPARTAC participants randomised to short-
course cART, 152 were given AZT-containing regimens. 
MCV values at baseline were available for 136 (89%) of 
whom 17 (12.5%) had a baseline HIV RNA <400 copies/ml 
and were, therefore, excluded from analyses. For the 
remaining 119, most (61%) were women, median (IQR) age 
at cART initiation was 29 (24, 38) years and BMI 24 (22, 
28) kg/m
2. Median time elapsed between estimated 
seroconversion and cART initiation was 86 (70, 111) days at 
CD4 and HIV RNA of 525 (421, 679) cells/mm
3 and 4.5 
(4.0, 5.1) log10
 copies/ml, respectively, and median MCV 87 
(82, 90) fL. Baseline MCV levels according to patient 
characteristics are presented in Table 1 and were lower 
among women, the majority of whom (71 of 73) were 
randomised from African sites. 
  The majority (95%) of participants started allocated 
cART on a regimen of zidovudine, lamivudine, and 
ritonavir-boosted lopinavir. One participant was additionally MCV as a Marker for AZT Adherence  The Open AIDS Journal, 2012, Volume 6    47 
prescribed enfuvirtide and five participants were prescribed 
didanosine instead of lamivudine. 
Changes in MCV Levels while on AZT-Containing 
Regimens 
  Four weeks after initiation of cART, 98 (88%) of 111 
participants with available HIV RNA results were classified 
as responders of whom 62 (63%) had achieved an HIV RNA 
<400 copies/ml (indicated by  in Fig. 1a). By 12 weeks, 84 
(85%) of 99 with available HIV RNA results were classified 
as responders, of whom 76 (90%) had achieved an HIV 
RNA <400 copies/ml (Fig. 1b). MCV data were missing for 
9 and 20 participants at weeks 4 and 12, respectively and, for 
the remaining participants, MCV levels increased to a 
median 89 (85, 92) at 4 weeks and 98 (92, 103) at 12 weeks, 
equivalent to mean overall increases of 2.5% (95% CI: 2.0, 
3.0) and 12.6% (11.2, 13.9) at those two time points, 
respectively. 
 Considering  responders  and  non-responders  separately, 
as defined at the relevant week, 4 weeks after starting cART, 
median MCV value was 90 (85, 93) and 83 (80, 91) fL for 
the two groups, respectively, corresponding to mean rises of 
2.6% (95% CI: 2.2, 3.2) and 1.1% (-0.6, 2.7). At 12 weeks, 
the difference between responders and non-responders was 
much more evident with median MCV levels of 99 (94, 105) 
and 89 (84, 91) fL, equivalent to a mean rise of 14% (95% 
CI: 12.7, 15.1) and 0.3% (-0.3, 3.0) for responders and non-
responders, respectively (Fig. 2i, ii). 
  The sensitivity and specificity for the use of each 
incremental change in MCV level against virological 
response are also shown in Fig. (2iii, iv). A 2% increase in 
MCV levels at 4 weeks has a sensitivity and specificity of 
62%. At week 12, an 8% increase in MCV levels from 
baseline has a sensitivity and specificity of 89%. Given the 
prevalence of non-response in our population at 12 weeks, 
such a rise has a negative predictive value, i.e. proportion 
identified as responders who are in fact responders, of 
97.9%, and a positive predictive value of 58.8%. 
  Restricting the definition of response to a drop in HIV 
RNA of  2 log10 copies/ml or reaching <400 copies/ml, 80 
(73%) and 81 (82%) of participants were classified as 
responders at weeks 4 and 12, respectively. This resulted in 
virtually no difference in sensitivity and specificity scores 
for different cut-off values of MCV percentage increase 
(results are not shown). 
Table 1.  Baseline Characteristics and Median Corpuscular Volume in SPARTAC Participants on AZT-Containing cART 
 
   N  Median  [IQR]  MCV 
Male 46  90  (87,92) 
Sex 
Female 73  85  (81,88) 
Sex between men  40  90  (88,93) 
Exposure category 
Sex between men & women  79  85  (81,89) 
<25 40  87  (83,90) 
25-29 23  85  (82,90) 
30-34 16  86  (81,90) 
35-39 13  89  (87,91) 
Age (years) 
40 27  88  (81,91) 
<20 10  87  (81,91) 
20-24 56  88  (84,91) 
25-29 26  87  (83,91) 
30 23  84  (81,87) 
Body Mass Index (kg/m
2) 
missing 4  88  (85,92) 
<350 18  88  (84,91) 
350-499 35  85  (80,90) 
500-749 45  87  (83,90) 
CD4 cell count (cells/mm
3)  
750 21  89  (86,91) 
<3 6  88  (82,90) 
3-4 26  86  (83,90) 
4-5 52  87  (83,89) 
Log10 HIV RNA (copies/mL) 
5 35  88  (82,91) 
African 71  85  (81,88) 
Country 
Non-African 48  90  (87,92) 48    The Open AIDS Journal, 2012, Volume 6  Mugisha et al. 
  Comparing reported adherence from the questionnaire 
with virological response, data were available from 102 
participants at week 4, of whom 90 (88%) reported not 
missing medication in the last 4 days. 89% of responders and 
71% of non-responders reported never missing any days, and 
1% of responders and 29% of non-responders reported 
missing medication on all 4 days. By 12 weeks, however, 
reported adherence was still generally high with, 97% (81 of 
83) of responders and 100% (12 of 12) of non-responders 
reporting missing, at most, one day of medication in the last 
4. Seventy-four (89%) and 11 (92%) responders and non-
responders, respectively, reported never missing medication 
at 12 weeks. 
  At 4 weeks, median MCV levels for responders who had 
reported missing no days of treatment in the last 4 were 
similar to responders who had reported at least one day of 
missed therapy (89, 77- 99 vs 88, 78- 98 fL, respectively). 
Levels were likewise similar for the two groups at 12 weeks 
(98, 75- 117 and 95, 81- 106 fL). 
Changes in MCV Levels on the Cessation of AZT-
Containing Regimen 
  MCV levels for Africans continued to remain lower than 
that of their counterparts from non-African sites throughout. 
Changes in absolute MCV levels from cART initiation to 24 
weeks after its cessation are shown in Fig. (3) separately for 
participants randomised at African and non-African sites. 
  For the 75 participants who were virological responders 
to therapy (at cessation of cART) MCV data were missing or 
censored for 9 (12%), 11 (15%) and 21 (28%) participants 4, 
12, and 24 weeks, respectively, after cART cessation. 
  At 4 weeks post cART cessation, median MCV levels 
remained high at 95 (90, 100) and 103 (95, 107) fL for 
Africans and non-Africans, respectively. By week 12, 28 
(82%) and 19 (58%) of Africans and non-Africans had 
experienced a decrease of 8%, compared to levels at 
cessation, and by 24 weeks these figures were 22 (96%) and 
25 (74%) respectively. This cut-off of 8% had a sensitivity 
and specificity of 89% for differentiating responders and 
non-responders (Fig. 2iv). 
DISCUSSION 
  Using data from participants enrolled in a randomised 
controlled trial with protocol-indicated cART cessation, we 
have shown that MCV levels may be useful in, not only 
identifying non-adherent, virologically non-responding 
patients, but also individuals who are not responding despite 
high adherence rates. A rise of at least 8% in MCV levels 12 
weeks after initiation of cART correctly identifies almost 
90% of virological responders, and a rise of <8% identifies 
 
Fig. (1). Changes in HIV RNA and MCV following initiation of cART at (a) week 4 and (b) week 12. Note: vertical line denotes 1 log drop 
in HIV RNA from baseline value separating virological responders from non-responders. 
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the same proportion of non-responders. This correlates with 
previous findings [16] and is valuable information given that 
a full blood count is easily performed and readily available 
in low-income countries and at, around $2, is a fraction of 
the cost of an HIV RNA measurement (P Kaleebu- personal 
communication). MCV levels could assist healthcare 
providers in identifying individuals who are not responding 
to AZT-based therapy, because of poor adherence, or even in 
spite of good adherence. 
  We observed a 2% rise in MCV levels at 4 weeks after 
starting cART suggesting a delay between virologic response 
and a change in MCV level. This is not surprising given the 
120-day average life span of an erythrocyte, suggesting that 
testing should occur at least 60 days from initiation of 
treatment i.e. when 50% of the red cell population would 
have been produced since cART initiation and a more 
significant rise could be expected. At any rate, using MCV 
levels to assess response to cART at such an early stage 
seems inappropriate. Indeed, we found that there is poor 
differentiation between those who experienced a fall in HIV 
RNA and those who did not. At best, a 2% rise in MCV, 
equivalent to the median rise attained by responders, at this 
stage is able to correctly identify only 62% of non-
responders. 
  At 12 weeks, however, a much greater increase in MCV 
level was observed for responders (14% vs 0.3% for non-
responders). MCV levels at this stage were much higher with 
median 96 and 103 fL for Africans and non-Africans, 
respectively, with at least 25% of participants in both groups 
attaining MCV measurements >100 fL. 
  We also observed that MCV levels in individuals 
randomised from the African sites were lower throughout 
compared to those of participants randomised from other 
sites, and in comparison with normal limits reported from 
high-income countries [20, 21]. Furthermore, once cART 
was stopped, a large decrease in MCV levels was 
experienced by a far bigger proportion of Africans, 
compared to non-Africans (82% vs 58%). These absolute 
levels and expected MCV decrease should be borne in mind 
when clinicians are assessing likely adherence in their 
patients, and raise the possibility that even initially adherent 
patients may no longer be taking their medication. 
  Ethnicity data were not collected in SPARTAC but we 
have assumed throughout that non-Africans were enrolled in 
 
Fig. (2). Percentage changes in MCV levels from baseline at (i) week 4 and (ii) week 12 for virological responders* (black) and non-
responders (grey), and sensitivity and specificity for use of change in MCV from baseline to correctly identify virological response at   
(iii) week 4 and (iv) week 12. * 1 log10 drop in HIV RNA from baseline or achieving <400 copies/ml. 
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non-African sites and only Africans were enrolled from 
African sites. Indeed, all those enrolled at sites in Uganda 
and South Africa were African women, the majority of 
whom had been enrolled on a trial to assess the efficacy of 
PRO2000, a microbicidal gel, with those seroconverting 
being offered the possibility of enrolling onto SPARTAC 
[22]. Their ethnicity is, therefore, recorded. At the non-
African sites, however, a degree of misclassification may 
have occurred which is likely to have tended to decrease the 
population average MCV level. This is unlikely, however, to 
have impacted on our main findings. 
  Additionally, we have been unable to adjust for iron 
levels, thalassaemia, folate or B12 deficiency, or other 
medications (including septrin and antiepileptics) which may 
affect MCV levels. 
  In the absence of HIV RNA measurements, patient-
reported adherence is often relied on. We found that this was 
not helpful in differentiating between those who 
virologically respond and those who had not. Although at 4 
weeks self-reported adherence levels were, indeed, lower for 
non-responders, by 12 weeks the trend had been reversed 
with, more or less, all non-responders claiming to be highly 
adherent. Clearly, the lack of sufficient fall in HIV RNA 
levels may not necessarily be related to non-adherence 
although this is perhaps usually the case. Other reasons can 
include existence of drug resistance and absorption issues. 
At any rate, our results do support the need to re-assess the 
prescribed cART regimen for patients whose MCV levels 
fail to increase by at least 8% 12 weeks after initiation of 
therapy particularly as there is also little differentiation in the 
increase in MCV levels in those reporting full adherence and 
those not. Once adherence is raised and discussed with the 
patient, other possible reasons for therapy failure should be 
explored and the cART regimen modified, if appropriate. 
  There are a number of other limitations to our study 
which warrant discussion. Firstly, we have not been able to 
differentiate between different levels of virological response. 
Nonetheless, we provide good evidence for the use of MCV 
to assess whether therapy has, indeed, been initiated and 
whether the patient is still on it, albeit possibly at less than 
ideal levels of adherence. We believe that this is still a 
valuable tool for the attending physician to assess the need 
for tackling adherence issues with the patient. 
  Secondly, we may have classified individuals without the 
necessary decline in HIV RNA as non-responders when they 
may have been responders. This would have resulted in us 
under-estimating both sensitivity and specificity however. 
Conversely, if some of our responders were not adherent, it 
would be difficult to conceive the reason for the HIV RNA 
declines they had experienced. 
  Thirdly, there were no study visits between 4 and 12 
weeks of therapy initiation and we are, therefore, unable to 
assess MCV levels, and likely adherence to therapy in the 
intervening period. This is unlikely to present as a major 
Fig. (3). Absolute MCV levels over time on AZT-containing regimens and upon cessation for participants achieving 1 log10 drop in HIV 
RNA or reaching <400 copies/ml at cessation of their allocated cART (i.e. 12 or 48 weeks). Note: data from all participants at baseline are 
included, and at 4 and 12 weeks after start of AZT-based cART only for those classified as responders at those time points. Levels after the 
cessation of AZT-based cART are only included for participants classified as responding to treatment at the cessation of their allocated 
course of therapy (i.e. 12 or 48 weeks). 
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problem, however, given that clinical assessment of a patient 
is unlikely to be scheduled earlier than 12 weeks. 
  Finally, our trial participants initiated cART at CD4 
levels far higher than those at which individuals initiate 
cART in HIV treatment and care programmes in African 
countries [23]. Whether changes in MCV levels are equally 
predictive in differentiating between those who have 
virologically responded and those who have not, is not 
known, but needs exploring by the investigators of cohorts 
with individuals initiating cART at much lower CD4 levels 
than ours. 
  It was not our intention to show that MCV can be used in 
lieu of HIV RNA. Indeed, we have shown that MCV levels 
do not match the speed of change of HIV RNA with 99 
(89%) of participants experiencing a significant drop in their 
HIV RNA levels by 4 weeks of cART initiation, whilst the 
rise in MCV at the time was modest. Our study does provide 
good evidence, however, to support the use of MCV levels to 
monitor patient adherence, and consequent likely success on 
therapy, in settings where HIV RNA measurements are too 
costly or otherwise unavailable. 
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